Skandinaviska Enskilda Banken AB publ Raises Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Skandinaviska Enskilda Banken AB publ increased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 11.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,790 shares of the biopharmaceutical company’s stock after purchasing an additional 3,430 shares during the period. Skandinaviska Enskilda Banken AB publ owned approximately 0.06% of Agios Pharmaceuticals worth $1,082,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in AGIO. Venturi Wealth Management LLC purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $33,000. Wingate Wealth Advisors Inc. purchased a new position in Agios Pharmaceuticals in the fourth quarter worth $53,000. Quest Partners LLC lifted its holdings in Agios Pharmaceuticals by 139.6% in the third quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 1,283 shares during the period. KBC Group NV boosted its position in shares of Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 611 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of Agios Pharmaceuticals during the 3rd quarter worth $146,000.

Insider Activity

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now directly owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Stock Up 3.4 %

NASDAQ AGIO opened at $31.99 on Tuesday. Agios Pharmaceuticals, Inc. has a fifty-two week low of $27.14 and a fifty-two week high of $62.58. The business has a fifty day moving average of $33.67 and a 200-day moving average of $41.67. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of 2.82 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on AGIO shares. StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Scotiabank boosted their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. Royal Bank of Canada raised their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Finally, HC Wainwright initiated coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They set a “buy” rating and a $58.00 target price on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Agios Pharmaceuticals currently has an average rating of “Hold” and an average target price of $56.57.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.